The biotech says sales of its first commercial therapy, Ryoncil, were $20 million in the quarter ending June 30.

Unlicensed e-bikes are flooding the market and our footpaths, causing accidents and fires. E-bikes as fast and as powerful as ...

Despite a soaring sharemarket, Morningstar warns ASX 20 profits are still falling. But major investors see a rebounding ...

Labor’s Dean Winter and Liberal Jeremy Rockliff are fighting it out in the second Tasmanian election in as many years. Polls ...

All options are likely on the table at Cettire, including being taken private, as the high-end luxury market is buffeted by ...

Construction starts and production in China, one of the world’s biggest steel markets, continue to fall. But shares in ...

The owners of Armaguard said they had no interest in selling the dominant banknote and coin transport business if banks and ...

Sharemarket investors have dismissed the Trump circus as noise. But for all the chaos, the US President’s big plan is still ...

Through new laws and less hostile regulators, the US President is making the sector great again in America. Australian ...

Mike Henry has delivered the sort of numbers he’s become known for. But BHP’s operational excellence make the issues at its ...

Jujubes can help with everything from insomnia to depression, according to Chinese medicine. Australian has signed a deal ...

The federal environment minister is yet to offer support for SA’s unfolding ocean catastrophe, as scientists ask the state to ...